A Randomized, Cross-over, Placebo-controlled, Double-blind, Single-center, Phase II Study of Cetuximab in Patients With Treatment-refractory, Non-malignant Severe Chronic Neuropathic Pain

Trial Profile

A Randomized, Cross-over, Placebo-controlled, Double-blind, Single-center, Phase II Study of Cetuximab in Patients With Treatment-refractory, Non-malignant Severe Chronic Neuropathic Pain

Completed
Phase of Trial: Phase II

Latest Information Update: 11 Nov 2016

At a glance

  • Drugs Cetuximab (Primary)
  • Indications Neuropathic pain
  • Focus Therapeutic Use
  • Acronyms NoTOPain
  • Most Recent Events

    • 07 Nov 2016 Status changed from active, no longer recruiting to completed.
    • 18 Oct 2016 Planned End Date changed from 1 Dec 2016 to 1 Oct 2016.
    • 18 Oct 2016 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top